References
1. Minard-Colin V, Brugieres L, Reiter A, et al. Non-Hodgkin Lymphoma in
Children and Adolescents: Progress Through Effective Collaboration,
Current Knowledge, and Challenges Ahead. J Clin Oncol . Sep 20
2015;33(27):2963-74. doi:10.1200/JCO.2014.59.5827
2. Gu X, Zheng R, Xia C, et al. Interactions between life expectancy and
the incidence and mortality rates of cancer in China: a population-based
cluster analysis. Cancer Commun (Lond) . Jul 3 2018;38(1):44.
doi:10.1186/s40880-018-0308-x
3. Marginean CO, Melit LE, Horvath E, Gozar H, Chincesan MI. Non-Hodgkin
lymphoma, diagnostic, and prognostic particularities in children - a
series of case reports and a review of the literature (CARE compliant).Medicine (Baltimore) . Feb 2018;97(8):e9802.
doi:10.1097/MD.0000000000009802
4. Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and
adolescent and young adult age spectrum. Hematology Am Soc Hematol
Educ Program . Dec 2 2016;2016(1):589-597.
doi:10.1182/asheducation-2016.1.589
5. Umerez M, Gutierrez-Camino A, Munoz-Maldonado C, Martin-Guerrero I,
Garcia-Orad A. MTHFR polymorphisms in childhood acute lymphoblastic
leukemia: influence on methotrexate therapy. Pharmgenomics Pers
Med . 2017;10:69-78. doi:10.2147/PGPM.S107047
6. He J, Liao XY, Zhu JH, et al. Association of MTHFR C677T and A1298C
polymorphisms with non-Hodgkin lymphoma susceptibility: evidence from a
meta-analysis. Sci Rep . Aug 22 2014;4:6159. doi:10.1038/srep06159
7. Gemmati D, Ongaro A, Tognazzo S, et al. Methylenetetrahydrofolate
reductase C677T and A1298C gene variants in adult non-Hodgkin’s lymphoma
patients: association with toxicity and survival. Haematologica .
Apr 2007;92(4):478-85. doi:10.3324/haematol.10587
8. De Mattia E, Toffoli G. C677T and A1298C MTHFR polymorphisms, a
challenge for antifolate and fluoropyrimidine-based therapy
personalisation. Eur J Cancer . May 2009;45(8):1333-51.
doi:10.1016/j.ejca.2008.12.004
9. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second
genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR)
associated with decreased enzyme activity. Mol Genet Metab . Jul
1998;64(3):169-72. doi:10.1006/mgme.1998.2714
10. Mashhadi MA, Miri-Moghaddam E, Arbabi N, et al. C677T and A1298C
polymorphisms of methylene tetrahydrofolate reductase in non-Hodgkin
lymphoma: southeast Iran. Tumori . Aug 2018;104(4):280-284.
doi:10.5301/tj.5000634
11. Skibola CF, Forrest MS, Coppede F, et al. Polymorphisms and
haplotypes in folate-metabolizing genes and risk of non-Hodgkin
lymphoma. Blood . Oct 1 2004;104(7):2155-62.
doi:10.1182/blood-2004-02-0557
12. Suthandiram S, Gan GG, Zain SM, et al. Polymorphisms in
methylenetetrahydrofolate reductase gene and risk of non-Hodgkin
lymphoma in a multi-ethnic population. J Hum Genet . May
2014;59(5):280-7. doi:10.1038/jhg.2014.19
13. Xie SZ, Liu ZZ, Yu JH, et al. Association between the MTHFR C677T
polymorphism and risk of cancer: evidence from 446 case-control studies.Tumour Biol . Nov 2015;36(11):8953-72.
doi:10.1007/s13277-015-3648-z
14. Kim HN, Lee IK, Kim YK, et al. Association between
folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma.Br J Haematol . Feb 2008;140(3):287-94.
doi:10.1111/j.1365-2141.2007.06893.x
15. Lee KM, Lan Q, Kricker A, et al. One-carbon metabolism gene
polymorphisms and risk of non-Hodgkin lymphoma in Australia. Hum
Genet . Dec 2007;122(5):525-33. doi:10.1007/s00439-007-0431-2
16. Ojha RP, Gurney JG. Methylenetetrahydrofolate reductase C677T and
overall survival in pediatric acute lymphoblastic leukemia: a systematic
review. Leuk Lymphoma . Jan 2014;55(1):67-73.
doi:10.3109/10428194.2013.792336
17. de Deus DM, de Lima EL, Seabra Silva RM, Leite EP, Cartaxo Muniz MT.
Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A
Polymorphisms on the Survival of Pediatric Patients with Acute
Lymphoblastic Leukemia. Leuk Res Treatment . 2012;2012:292043.
doi:10.1155/2012/292043
18. Karas Kuzelicki N, Milek M, Jazbec J, Mlinaric-Rascan I.
5,10-Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes
reduce the risk of relapse-related acute lymphoblastic leukemia (ALL).Leuk Res . Oct 2009;33(10):1344-8.
doi:10.1016/j.leukres.2008.12.011
19. Lambrecht L, Sleurs C, Labarque V, Dhooge C, Uyttebroeck A. The role
of the MTHFR C677T polymorphism in methotrexate-induced toxicity in
pediatric osteosarcoma patients. Pharmacogenomics .
2017;18(8):787-795.
20. Zhu L, Wang F, Hu F, et al. Association between MTHFR polymorphisms
and overall survival of colorectal cancer patients in Northeast China.Med Oncol . Mar 2013;30(1):467. doi:10.1007/s12032-013-0467-1
21. Yeh CC, Lai CY, Chang SN, et al. Polymorphisms of MTHFR C677T and
A1298C associated with survival in patients with colorectal cancer
treated with 5-fluorouracil-based chemotherapy. Int J Clin Oncol .
Jun 2017;22(3):484-493. doi:10.1007/s10147-016-1080-z
22. Liu D, Li X, Li X, et al. CDA and MTHFR polymorphisms are associated
with clinical outcomes in gastroenteric cancer patients treated with
capecitabine-based chemotherapy. Cancer Chemother Pharmacol . May
2019;83(5):939-949. doi:10.1007/s00280-019-03809-2
23. Ose J, Botma A, Balavarca Y, et al. Pathway analysis of genetic
variants in folate-mediated one-carbon metabolism-related genes and
survival in a prospectively followed cohort of colorectal cancer
patients. Cancer Med . May 29 2018;doi:10.1002/cam4.1407
24. Osian G, Procopciuc L, Vlad L, Iancu C, Mocan T, Mocan L. C677T and
A1298C mutations in the MTHFR gene and survival in colorectal cancer.J Gastrointestin Liver Dis . Dec 2009;18(4):455-60.
25. Rosolen A, Perkins SL, Pinkerton CR, et al. Revised International
Pediatric Non-Hodgkin Lymphoma Staging System. J Clin Oncol . Jun
20 2015;33(18):2112-8. doi:10.1200/JCO.2014.59.7203
26. Sandlund JT, Guillerman RP, Perkins SL, et al. International
Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol .
Jun 20 2015;33(18):2106-11. doi:10.1200/JCO.2014.59.0745
27. D’Angelo V, Ramaglia M, Iannotta A, et al. Influence of
methylenetetrahydrofolate reductase gene polymorphisms on the outcome of
pediatric patients with non-Hodgkin lymphoma treated with high-dose
methotrexate. Leuk Lymphoma . Dec 2013;54(12):2639-44.
doi:10.3109/10428194.2013.784758
28. Gross TG, Termuhlen AM. Pediatric non-Hodgkin’s lymphoma. Curr
Oncol Rep . Nov 2007;9(6):459-65. doi:10.1007/s11912-007-0064-6
29. Choeyprasert W, Anurathapan U, Pakakasama S, et al. Pediatric
non-Hodgkin lymphoma: Characteristics, stratification, and treatment at
a single institute in Thailand. Pediatr Int . Jan
2019;61(1):49-57. doi:10.1111/ped.13739
30. Suh JK, Gao YJ, Tang JY, et al. Clinical Characteristics and
Treatment Outcomes of Pediatric Patients with Non-Hodgkin Lymphoma in
East Asia. Cancer Res Treat . Apr 2020;52(2):359-368.
doi:10.4143/crt.2019.219
31. Woessmann W, Seidemann K, Mann G, et al. The impact of the
methotrexate administration schedule and dose in the treatment of
children and adolescents with B-cell neoplasms: a report of the BFM
Group Study NHL-BFM95. Blood . Feb 1 2005;105(3):948-58.
doi:10.1182/blood-2004-03-0973
32. Muller J, Csoka M, Jakab Z, Ponyi A, Erlaky H, Kovacs G. Treatment
of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with
NHL-BFM 90 and 95 protocols. Pediatr Blood Cancer . Mar
2008;50(3):633-5. doi:10.1002/pbc.21144
33. Burkhardt B, Oschlies I, Klapper W, et al. Non-Hodgkin’s lymphoma in
adolescents: experiences in 378 adolescent NHL patients treated
according to pediatric NHL-BFM protocols. Leukemia . Jan
2011;25(1):153-60. doi:10.1038/leu.2010.245
34. Shimasaki N, Mori T, Samejima H, et al. Effects of
methylenetetrahydrofolate reductase and reduced folate carrier 1
polymorphisms on high-dose methotrexate-induced toxicities in children
with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol
Oncol . Feb 2006;28(2):64-8. doi:10.1097/01.mph.0000198269.61948.90
35. Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1
polymorphisms on toxicities during maintenance chemotherapy for
childhood acute lymphoblastic leukemia or lymphoma. J Pediatr
Hematol Oncol . May 2008;30(5):347-52. doi:10.1097/MPH.0b013e318165b25d
36. Seidemann K, Book M, Zimmermann M, et al. MTHFR 677
(C–>T) polymorphism is not relevant for prognosis or
therapy-associated toxicity in pediatric NHL: results from 484 patients
of multicenter trial NHL-BFM 95. Ann Hematol . May
2006;85(5):291-300. doi:10.1007/s00277-005-0072-2
37. Pandith AA, Qasim I, Zahoor W, Shah P, Bhat AR. ACE I/D sequence
variants but not MTHFR C677T, is strongly linked to malignant glioma
risk and its variant DD genotype may act as a promising predictive
biomarker for overall survival of glioma patients. Gene . Jan 10
2018;639:62-68. doi:10.1016/j.gene.2017.10.013
38. Shrubsole MJ, Shu XO, Ruan ZX, et al. MTHFR genotypes and breast
cancer survival after surgery and chemotherapy: a report from the
Shanghai Breast Cancer Study. Breast Cancer Res Treat . May
2005;91(1):73-9. doi:10.1007/s10549-004-7265-6
39. Lambrecht L, Sleurs C, Labarque V, et al. The role of the MTHFR
C677T polymorphism in methotrexate-induced toxicity in pediatric
osteosarcoma patients. Pharmacogenomics . Jun 2017;18(8):787-795.
doi:10.2217/pgs-2017-0013
40. Xie L, Guo W, Yang Y, Ji T, Xu J. More severe toxicity of genetic
polymorphisms on MTHFR activity in osteosarcoma patients treated with
high-dose methotrexate. Oncotarget . Feb 20
2018;9(14):11465-11476. doi:10.18632/oncotarget.23222
41. Visani G, Loscocco F, Ruzzo A, et al. MTHFR, TS and XRCC1 genetic
variants may affect survival in patients with myelodysplastic syndromes
treated with supportive care or azacitidine. Pharmacogenomics J .
May 22 2018;18(3):444-449. doi:10.1038/tpj.2017.48
42. Zetterberg H, Rymo L, Coppola A, D’Angelo A, Spandidos DA, Blennow
K. Reply to ‘MTHFR C677T and A1298C polymorphisms and mutated sequences
occurring in cis’. European Journal of Human Genetics . 2002/10/01
2002;10(10):579-582. doi:10.1038/sj.ejhg.5200863
43. Sandlund JT. Non-Hodgkin Lymphoma in Children. Curr Hematol
Malig Rep . Sep 2015;10(3):237-243. doi:10.1007/s11899-015-0277-y